Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Jan 4:23:20-23.
doi: 10.1016/j.gore.2018.01.002. eCollection 2018 Feb.

Aggressive neuroendocrine tumor of the ovary with multiple metastases treated with everolimus: A case report

Michiko Kaiho-Sakuma  1 , Masafumi Toyoshima  1 , Mika Watanabe  2 , Asami Toki  1 , Satomi Kameda  1 , Takamichi Minato  1 , Hitoshi Niikura  1 , Nobuo Yaegashi  1
Affiliations
Case Reports

Aggressive neuroendocrine tumor of the ovary with multiple metastases treated with everolimus: A case report

Michiko Kaiho-Sakuma et al. Gynecol Oncol Rep. .

Abstract

•Neuroendocrine tumors (NETs) frequently occur in the lungs or the gastrointestinal tract; they are uncommon in the ovary.•The mammalian target of rapamycin (mTOR) pathway has been reported as a treatment for advanced NETs.•We describe a patient with an aggressive primary ovarian NET, successfully treated with everolimus (an mTOR inhibitor).

Keywords: BEP, bleomycin, etoposide, and cisplatin; CA-125, carbohydrate antigen 125; CD56, cluster of differentiation 56; CDX2, caudal-type homeobox transcription factor 2; CT, computed tomography; Carcinoid; EMA, epithelial membrane antigen; Everolimus; FIGO, International Federation of Gynecology and Obstetrics; MRI, magnetic resonance imaging; Multiple metastases; NETs, neuroendocrine tumors; Neuroendocrine tumor; Ovary; mTOR, mammalian target of rapamycin.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Imaging studies. (A) T2-weighted magnetic resonance imaging (MRI), sagittal section. (B) T1-weighted, enhanced MRI, horizontal section. (C) Computed tomography (CT) showing metastasis to the liver; (D) CT showing metastasis to the right kidney.
Fig. 2
Fig. 2
Pathological findings. (A) Gross appearance of the resected ovarian tumor shows a 20-cm, solid mass with an irregular, smooth surface. (B) The cut surface shows fleshy, tan-yellow, heterogeneous tissue with focal hemorrhage, necrosis, and cystic change. (C) Hematoxylin and eosin staining. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 3
Fig. 3
Immunohistochemistry. The tumor cells are strongly positive for (A) synaptophysin and (B) chromogranin A. (C) The tumor cells are negative for inhibinα. (D) The Ki-67 index is 17%.
See this image and copyright information in PMC

References

    1. Chan J., Kulke M. Targeting the mTOR signaling pathway in neuroendocrine tumors. Curr. Treat. Options in Oncol. 2014;15:365–379. - PMC - PubMed
    1. Cives M., Strosberg J. Treatment strategies for metastatic neuroendocrine tumors of the gastrointestinal tract. Curr. Treat. Options in Oncol. 2017;18 - PubMed
    1. Desouki M.M., Lioyd J., Xu H., Cao D., Barner R., Zhao C. CDX2 may be a useful marker to distinguish primary ovarian carcinoid from gastrointestinal metastatic carcinoids to the ovary. Hum. Pathol. 2013;44:2536–2541. - PubMed
    1. Gardner G.J., Reidy-Lagunes D., Gehrig P.A. Neuroendocrine tumors of the gynecologic tract: a Society of Gynecologic Oncology (SGO) clinical document. Gynecol. Oncol. 2011;122:190–198. - PubMed
    1. Jamar F., Fiasse R., Leners N., Pauwels S. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J. Nucl. Med. 1995;36:542–549. - PubMed

Publication types